NEW YORK (TheStreet) -- Protalix BioTherapeutics (PLX - Get Report) surged Thursday after the company co-announced with Pfizer (PFE) that the FDA had approved the expansion of ELELYSO for injection in pediatric patients.
The expansion means the drug is now indicated for long-term enzyme replacement therapy, or ERT, for both adult and pediatric patients who have been diagnosed with Type 1 Gaucher disease.
Type 1 is the most common form of the inherited disease, which causes enlargement of the liver and spleen, anemia, decline in blood platelets leading to bruising, lung disease, and bone problems such as pain, fractures and arthritis.
Must Read: 50 Stocks Hedge Funds Love
Protalix was up 13.69% to $2.74 at 2:45 p.m.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.